Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Celltrion chooses TEVA as biosimilar distributor in N. America - Pulse by Maeil Business News Korea
Teva, Celltrion Launch Fourth Trastuzumab Biosimilar
Celltrion FDA warning causes headache for Teva's biologics ambition
FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label - MedCity News
Teva teams with Celltrion in $160m biosimilar deal - Globes
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Celltrion clinches 110 bln-won drug substance supply deal from Teva | Yonhap News Agency
Teva, Celltrion launch Herceptin biosimilar in US - Globes
Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS | Business Wire
Teva, Celltrion launch Herceptin biosimilar in US - Globes
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva and Celltrion Announce the Launch in the U.S. of Biosimilar to Rituximab for Rheumatoid Arthritis | TechnoPharma | Дзен
Celltrion partners with Canada's iProgen Biotech
Celltrion and Teva Snag Second Biosimilar Approval of a Genentech Drug | BioSpace
Celltrion, Teva Suit Says Biosimilar Patent Claims Over-the-Top
Teva buys US rights to Celltrion biosimilars -
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership - Drug Discovery and Development
Teva and Celltrion Launch Trastuzumab Biosimilar in U.S. - Big Molecule Watch
Celltrion stuns the market with merger and expansion plan for this year - Pulse by Maeil Business News Korea
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Partners Teva/Celltrion Seek the Jump on Pfizer, Launch Their Rituximab Biosimilar Next Week
Teva On Tenterhooks Over Fremanezumab As Celltrion Gets CRLs :: Scrip
Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents | Biosimilars Law Bulletin
